| Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe |
2007-003472-19: Determining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring. |
|
|
| Ongoing | 4 | 178 | Europe | foscarnet, Ganciclovir, valganciclovir, Intravenous infusion, Powder for injection*, Film-coated tablet, Foscavir, Cymeve IV, Valcyte 450mg film-coated tablets | Royal Free Hampstead NHS Trust | Transplant recipients with CMV infection. | | | | |
2010-020551-31: Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation. |
|
|
| Ongoing | 4 | 100 | Europe | Valcyte, Cymevene, Valcyte, Cymevene, Valcyte, Cymevene | Nordic Bone and Marrow Transplantation Group | First cytomegalovirus DNAemia after stem cell transplantation | | | | |
2013-004445-17: STUDY FOR THE PREDICTION OF CYTOMEGALOVIRUS INFECTION IN RENAL TRANSPLANT PATIENTS BY THE EVALUATION OF THE IMMUNE RESPONSE BEFORE TRANSPLANTATION ESTUDIO PARA LA PREDICCIÓN DE LA INFECCION POR CITOMEGALOVIRUS EN PACIENTES TRANSPLANTADOS RENALES MEDIANTE LA EVALUACIÓN DE LA RESPUESTA INMUNE ANTES DEL TRANSPLANTE |
|
|
| Ongoing | 4 | 160 | Europe | valcyte, CYMEVENE, VALCYTE, valcyte, CYMEVENE, VALCYTE | HOSPITAL UNIVERSITARI DE BELLVITGE, IDIBELL- INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE | cytomegalovirus infection in renal tranplant recipients Infección por citomegalovirus en receptores de un transplante renal | | | | |
2011-005708-13: Multicenter clinical trial comparing the efficacy and safety of two strategies in the prevention of cytomegalovirus infection in kidney transplant recipients. Ensayo clínico multicéntrico de comparación de la eficacia y seguridad de dos estrategias en la prevención de la infección por citomegalovirus en trasplantados renales. |
|
|
| Ongoing | 4 | 354 | Europe | Valcyte 450 mg, Cymevene inyectable, Valcyte 450 mg comprimidos recubiertos con película, Cymevene inyectable, Valcyte 450 mg comprimidos recubiertos con película, Cymevene inyectable | Fundación para la Investigación Biomedica del Hospital 12 de Octubre, Instituto de Salud Carlos III | Prophylaxis of cytomegalovirus infection in seropositive kidney transplant recipients. Profilaxis de la infección por citomegalovirus en receptores seropositivos de trasplante renal. | | | | |
| Active, not recruiting | 4 | 92 | | | ass. Prof. Tomas Reischig, M.D., Ph.D., Project ED2.1.00/03.0076 from European Regional Development Fund., Charles University Research Fund (project number P36), Charles University Research Fund (Progres Q39) | Cytomegalovirus infection after renal transplantation | | | | |
2019-001032-54: Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative colitis (UC) requiring vedolizumab therapy: a randomized clinical trial comparing a strategy with or without antiviral therapy Impact du traitement anti-cytomégalovirus (valganciclovir) dans la prise en charge des poussées de rectocolite hémorragique (RCH) nécessitant un traitement par vedolizumab : étude thérapeutique randomisée comparant une stratégie avec ou sans antiviral |
|
|
| Not yet recruiting | 4 | 120 | Europe | valganciclovir, vedolizumab, Coated tablet, Powder for suspension for injection, valganciclovir, vedolizumab | CHU de Saint Etienne, CHU de Saint Etienne | Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 1 and 2 biopsies of the inflammatory tissue and presence of a CMV infection in the inflammatory tissue objectified by a viral load greater than 5 IU / 100000 cells by qPCR. Patient avec poussée inflammatoire de rectocolite hémorragique sous anti-TNF avec score Mayo endoscopique > 2 avec infection à CMV dans le tissu inflammatoire (charge virale supérieure à 5 UI/100000cellules), Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an endoscopic Mayo score> 2 and presence of a CMV infection (inflammatory tissue = 5UI/100000cells) Patient avec poussée inflammatoire de rectocolite hémorragique sous anti-TNF avec score Mayo endo > 2 avec infection à CMV dans le tissu inflammatoire (charge virale supérieure à 5 UI/100000cell), Diseases [C] - Digestive System Diseases [C06] | | | | |
2019-002233-11: Multicenter clinical trial to evaluate the efficacy of a preventive strategy against CMV infection in heart transplant patients, based on T cells responses. Ensayo clínico multicéntrico para evaluar la eficacia de una estrategia preventiva contra la infección por CMV en pacientes con trasplante de corazón, basado en la respuesta basal específica de las células T. |
|
|
| Ongoing | 4 | 188 | Europe | Valganciclovir, Ganciclovir, Capsule, Solution for solution for injection, Valganciclovir, Ganciclovir | Dr. José González Costello.Unidad de Insuficiencia cardíaca avanzada y Trasplante cardíaco. Hospital Univ. Bellvitge, Fondos de Investigación Sanitarias (FIS) INSTITUTO CARLOS III, Beca SEC: Proyecto de Investigación de trasplante cardíaco de la sección de insuficiencia cardíaca | We will investigate the benefits of monitoring the CMV-specific cellular response using the ELISPOT INF-y technique in patients with a positive serology against CMV, allowing the individualization of the preventión strategy. The drugs valganciclovir and ganciclovir will be used in seropositive patitens (IgG against CMV), not indicated in the data sheet but accepted as part of the habitual prophylaxis of heart transplant patient according to the clinical practice guidelines. Se investigarán los posibles beneficios de una monitorización de la respuesta celular CMV-específica mediante la técnica ElISPOT IFN-y en pac. con serología positiva frente al CMV,permitiendo individualizar el tipo de estrategia de prevención.Se harán uso de los fármacos valganciclovir y ganciclovir en pac. seropositivos (IgG positiva para CMV),no indicado en ficha técnica pero sí aceptado como parte de la profilaxis habitual de pac. trasplantados cardíacos según las guías de práctica habitual., To evaluate the efficacy of an individualized preventive strategy against cytomegalovirus infection in heart transplant patients Evaluar la eficacia de una estrategia preventiva e individualizada frente a la infección por Citomegalovirus en pacientes trasplantados cardíacos, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ELISPOT-TC, NCT04278547: Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response |
|
|
| Recruiting | 4 | 188 | Europe | ELISPOT IFN-γ assay, Valganciclovir | Hospital Universitari de Bellvitge, Instituto de Salud Carlos III, Sociedad Española de Cardiología | Heart Transplant Infection, CMV Infection | 03/22 | 03/23 | | |
ChiCTR2100044233: A multicentre clinical study on the diagnosis and treatment of sensorineural deafness caused by congenital cytomegalovirus infection |
|
|
| Recruiting | 4 | 340 | | Ganciclovir injection 6mg/kg/ time, or valganciclovir oral 16mg/kg/ time, treatment course: 3 weeks BID + 1 week QD ;Ganciclovir injection 6mg/kg/ time, or valganciclovir oral 16mg/kg/ time, treatment course: 6 weeks BID ;Ganciclovir injection 6mg/kg/ time, or valganciclovir oral 16mg/kg/ time, treatment course: 6 weeks BID ;Ganciclovir injection 6mg/kg/ time, or valganciclovir oral 16mg/kg/ time, course of treatment: 4 months BID | Children's Hospital Affiliated to Zhejiang University Medical College; Children's Hospital Affiliated to Zhejiang University Medical College, National Clinical Medical Research Center | Congenital cytomegalovirus infection | | | | |
NCT06001320: De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Transplant Recipients |
|
|
| Recruiting | 4 | 60 | US | Letermovir 480 mg once daily, Historical/Control | Virginia Commonwealth University, Merck Sharp & Dohme LLC | Kidney Transplant; Complications, CMV | 09/25 | 09/26 | | |
NCT06034925: Maribavir Vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients |
|
|
| Active, not recruiting | 4 | 70 | US | Maribavir, Valganciclovir | Medical University of South Carolina, Takeda | Transplant Complication, CMV | 11/25 | 11/25 | | |
2008-005508-14: A six weeks versus six months Study of oral valgancoclovir medicine and dummy medicine in infants with congenital cytomegalovirus infection symtoms. |
|
|
| Ongoing | 3 | 20 | Europe | Valganciclovir, Valcyte 50 mg/ml Powder for Oral Solution, Valcyte 50 mg/ml Powder for Oral Solution | University College london, National Institute of Allergy and Infectious diseases of the National Institutes of Health | Symptomatic Congenital Cytomegalovirus. | | | | |
2015-004406-42: Prophylactic treatment with Valganciclovir in kidney transplant CMV-seropositve patients. Profilaxis del tratamiento con Valganciclovir en transplantados renales CMV seropositivo |
|
|
| Ongoing | 3 | 150 | Europe | Tablet, VALCYTE 450 mg comprimidos recubiertos con película | FIBICO, FIBICO | Kidney transplant cytomegalovirus-seropositive Trasplante renal citomegalovirus seropositivo, Kidney transplant cytomegalovirus-seropositive Trasplante renal citomegalovirus seropositivo, Diseases [C] - Virus Diseases [C02] | | | | |
2018-003300-39: Clinical trial of efficacy and safety of the combination of reduced duration prophylaxis followed by immuno-guided prophylaxis in lung transplant recipients. Ensayo clínico de eficacia y seguridad de la combinación de profilaxis de duración reducida seguida de profilaxis inmunoguiada en pacientes transplantados de pulmón. |
|
|
| Not yet recruiting | 3 | 150 | Europe | Tablet, Powder for concentrate for solution for infusion, VALCYTE, CYMEVENE | Fundación para la Investigación Biomédica de Córdoba, Instituto de Salud Carlos III | Cytomegalovirus Infection in subjects who underwent lung transplantation. Infección por citomegalovirus en pacientes trasplantados de pulmón., Virus Infection in subjects who underwent lung transplantation. Infección por virus en pacientes trasplantados de pulmón., Diseases [C] - Virus Diseases [C02] | | | | |
2022-002556-39: Efficacy of a preventive strategy for immuno-guided cytomegalovirus infection compared to a universal prophylactic strategy in renal transplant recipients |
|
|
| Not yet recruiting | 3 | 144 | Europe | valganciclovir, ROVALCYTE 450 mg, comprimé pelliculé, Capsule, ROVALCYTE 450 mg, ROCHE | DRCI - CHU de Rouen, DRCI - CHU de Rouen | Patients receiving a kidney transplant (1 to 12 days post-transplant), Patients receiving a kidney transplant (1 to 12 days post-transplant), Not possible to specify | | | | |
CYTOCOR, NCT03699254: Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients. |
|
|
| Completed | 3 | 150 | Europe | Valganciclovir, Valcyte, Ganciclovir, Cymevene | Maimónides Biomedical Research Institute of Córdoba, Instituto de Salud Carlos III | Transplantation Infection, Cytomegalovirus Infections | 05/23 | 05/23 | | |
CYTOVEDO, NCT04064697: Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy |
|
|
| Terminated | 3 | 6 | Europe | Valganciclovir, antiviral therapy | Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France | Ulcerative Colitis, Unspecified | 11/23 | 02/24 | | |
| Recruiting | 3 | 80 | Europe | Letermovir, Valganciclovir, Letermovir placebo | Assistance Publique - Hôpitaux de Paris | Cytomegalovirus Infection | 09/27 | 11/27 | | |
NCT06439342: A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections |
|
|
| Not yet recruiting | 3 | 20 | RoW | Maribavir, TAK-620 | Takeda | Cytomegalovirus (CMV) | 02/27 | 02/27 | | |
| Not yet recruiting | 2/3 | 99 | NA | Topical ganciclovir versus oral valganciclovir versus placebo | Francis I. Proctor Foundation, National Taiwan University, Chulalongkorn University, Khon Kaen University | Uveitis, Anterior, Cytomegalovirus Infections | 12/21 | 04/22 | | |
STACCATO, NCT03586284: Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes |
|
|
| Recruiting | 2/3 | 99 | US, RoW | Valganciclovir Hydrochloride, Ganciclovir Sodium, Placebo Oral Tablet, Topical placebo | University of California, San Francisco, Huang Pacific Foundation, Khon Kaen University, King Chulalongkorn Memorial Hospital | Cytomegalovirus Anterior Uveitis | 03/25 | 03/25 | | |
EMPIRICAL, NCT03915366: Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia |
|
|
| Active, not recruiting | 2/3 | 563 | Europe, RoW | Valganciclovir Oral Solution [Valcyte], Treatment for CMV, Tuberculostatic Agents, Treatment for TB | Hospital Universitario 12 de Octubre, University Hospital, Bordeaux, Institut National de la Santé Et de la Recherche Médicale, France, PENTA Foundation, Centre Hospitalier Cocody, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Eduardo Mondlane University, Centro de Investigação em Saúde de Manhiça, Stichting Katholieke Universiteit, Barcelona Institute for Global Health, University of Lincoln, Makerere University, University Teaching Hospital, Lusaka, Zambia, University of Zimbabwe, Kamuzu Central Hospital, Servicio Madrileño de Salud, Madrid, Spain | Pneumonia, HIV/AIDS, Tuberculosis, Cytomegalovirus Infections | 01/25 | 07/25 | | |
| Ongoing | 2 | 54 | Europe | Valganciclovir, Powder for oral solution, Valcyte, Rovalcyte, or Valixa | University College London, NIH | Children born with congenital CMV infection may develop sequelae on follow-up, particularly sensorineural hearing loss. A recent systematic review reports that 13.5% of babies with congenital CMV infection develop sensorineural hearing loss on follow-up. Of babies who develop sensorineural hearing loss, more than a quarter of babies born with symptomatic congenital CMV disease and almost 40% of babies born with asymptomatic CMV infection will have delayed-onset hearing loss., Deafness., Diseases [C] - Virus Diseases [C02] | | | | |
2011-001449-34: Study for the treatment of cytomegalovirus infection, in transplanted patients Estudio para el tratamiento de la infeccion por citomegalovirus, en pacientes trasplantados. |
|
|
| Ongoing | 2 | 64 | Europe | GANCICLOVIR, FOSCARNET, VALGANCICLOVIR, CYMEVENE, FOSCAVIR, VALCYTE, CYMEVENE, FOSCAVIR, VALCYTE | FUNDACION INVESTIGACION HOSPITAL CLINICO DE VALENCIA-INSTITUTO DE INVESTIGACION SANITARIA INCLIVA, Ministerio de Sanidad y Politica Social | Cytomegalovirus infection in patients treated with hematopoietic allogenic transplant INFECCION POR CITOMEGALOVIRUS EN PACIENTES TRATADOS CON TRASPLANTE HEMATOPOYETICO ALOGENICO | | | | |
2019-001083-30: A clinical trial to evaluate the effect of the anti-viral drug Valganciclovir in brain tumor patients En kliniska studie som avser utvärdera effekten av anti-virus läkemedlet valganciclovir hos hjärntumör patienter. |
|
|
| Not yet recruiting | 2 | 220 | Europe | valganciclovir, Tablet, valganciclovir Valcyte | Karolinska Institutet, Karolinska Instituet | Glioblastoma is an incurable brain tumor with very dismal prognosis. Substantial evidence demonstrates that cytomegalovirus (CMV) is present in 90-100% of malignant glioblastoma.We have observed that valganciclovir is well tolerated among glioblastoma patients receiving temozolomide and radiation therapy. We further observed that treatment with valganciclovir may enhance the survival chances for glioblastoma patients. We aim to assess the efficacy of Valganciclovir in glioblastoma patients. Glioblastom är en obotlig hjärntumör med mycket dyster prognos. Bevis talar för att cytomegalovirus (CMV) är närvarande i 90-100% malignt glioblastom. Vi har observerat att valganciklovir tolereras väl bland glioblastompatienter som får temozolomid och strålbehandling. Vi observerade vidare att behandling med valganciklovir tycks kunna öka överlevnadschanserna för patienter med glioblastom. Vi strävar efter att utvärdera effekten av Valganciclovir hos patienter med glioblastom., Brain tumor glioblastoma Hjärntumören glioblastom, Diseases [C] - Cancer [C04] | | | | |
2017-002912-15: Secondary prophylaxis after CMV disease in kidney transplants targeted by γδ T cells monitoring. Prophylaxie secondaire ciblée par l’immunosurveillance des lymphocytes T γδ après infection à CMV. |
|
|
| Not yet recruiting | 2 | 37 | Europe | valganciclovir, Tablet, Injection, Rovalcyte, Cymevan | CHU de Bordeaux, CHU de Bordeaux | Kidney transplants patients Patients greffés rénaux, Kidney transplants patients Patients greffés rénaux, Diseases [C] - Virus Diseases [C02] | | | | |
2020-005197-10: Nanatinostat and Valganciclovir in R/R EBV+ Lymphoma (“NAVAL-1”) |
|
|
| Not yet recruiting | 2 | 150 | Europe | Nanatinostat, Valganciclovir, ganciclovir, VRx-3996, Film-coated tablet, Powder for concentrate for solution for infusion, Valganciclovir hydrochloride | Viracta Therapeutics, Inc., Viracta Therapeutics, Inc. | Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas, Diseases [C] - Cancer [C04] | | | | |
ValEAR, NCT03107871: Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants |
|
|
| Active, not recruiting | 2 | 52 | US | Valganciclovir, Valcyte, Simple Syrup, Sucrose Water | Albert Park, National Institute on Deafness and Other Communication Disorders (NIDCD), Genentech, Inc. | Cmv Congenital, CMV, Congenital Cmv, SNHL, Sensorineural Hearing Loss | 07/22 | 07/24 | | |
NAVAL-1, NCT05011058: An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas |
|
|
| Recruiting | 2 | 140 | Europe, Canada, US, RoW | Nanatinostat in combination with valganciclovir | Viracta Therapeutics, Inc. | Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma, EBV-Positive DLBCL, NOS, EBV Associated Lymphoma, EBV Related PTCL, NOS | 07/25 | 12/26 | | |
NCT05041426: Letermovir for CMV Prevention After Lung Transplantation |
|
|
| Recruiting | 2 | 30 | US | Letermovir, Prevymis, Valganciclovir | Fernanda P Silveira, MD, MS, Merck Sharp & Dohme LLC | Lung Transplant, CMV | 07/25 | 07/25 | | |
VIGAS2, NCT04116411: A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients |
|
|
| Recruiting | 2 | 220 | Europe | Valganciclovir Tablets, Valcyte, ValGANcilovir, Valganciclovir 450 mg, J05AB14, Valganciclovir oral, Temozolomide 120 mg, Temozolomide pill, Temozolomide tablet, Radiotherapy 60 Gy, Radiation, Placebo oral tablet, Placebos | Cecilia Soderberg-Naucler, Karolinska University Hospital, Karolinska Institutet | Glioblastoma Multiforme | 07/27 | 07/27 | | |
NCT05708755: CMV Immunity Monitoring in Lung Transplant Recipients |
|
|
| Recruiting | 2 | 50 | US | Cytomegalovirus T Cell Immunity Panel (CMV-TCIP), Viracor inSIGHT, Donor-Derived Cell-Free DNA (dd-cfDNA) Assay, Viracor TRAC, Valganciclovir | NYU Langone Health, Viracor Eurofins | Lung Transplant; Complications | 09/25 | 09/26 | | |
NCT00092222: Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity |
|
|
| Active, not recruiting | 2 | 75 | US | Etoposide, Interferon-alpha, Rituximab, Zidovudine, Liposomal Doxorubicin, Bortezomib, Valganciclovir, Doxorubicin, Vincristine, Cyclophosphamide, Filgrastim (G-CSF), Prednisone, Sirolimus, Observation Only | National Cancer Institute (NCI) | Lymphoproliferative Disorder, HHV-8, Malignancy, HIV | 10/25 | 10/25 | | |
LETERCOR, NCT06057194: Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. |
|
|
| Not yet recruiting | 2 | 90 | Europe | Letermovir 240 mg Oral Tablet | Maimónides Biomedical Research Institute of Córdoba, MERCK SHARP & DOHME DE ESPAÑA S.A. | Infections, Cytomegalovirus | 04/27 | 04/27 | | |
| Recruiting | 2 | 23 | US | CMV Cytotoxic T-Lymphocytes, CTLs, Anti-viral Therapy, valganciclovir, ganciclovir | New York Medical College | Congenital Cytomegaloviral (CMV) Disease | 10/27 | 10/28 | | |
2010-022444-20: PHASE I-II STUDY OF GEMCITABINE AND VALPROIC ACID PLUS VALGANCICLOVIR IN PATIENTS WITH ADVANCED NASOPHARYNGEAL CARCINOMA |
|
|
| Ongoing | 1/2 | 20 | Europe | Valcyte, Valcyte | ZonMW | Patient has histological confirmed residual, recurrent or metastatic EBV-positive Nasopharynx carcinoma that has failed conventional curative treatments and deemed incurable, or patient refuses further treatment with conventional methods because of associated morbidity/mortality or private reasons. | | | | |
ChiCTR-OIN-17012863: Clinical study of PD-1 inhibitor combined with valganciclovir treatment for relapsed and refractory brain tumors |
|
|
| Recruiting | 1/2 | 30 | | Valganciclovir table QD+PD-1 inhitor IV Q3W | Renji Hospital, Shanghai Jiao Tong University School of Medicine; Renji Hospital, Shanghai Jiao Tong University School of Medicine, self-funding | Malignant Glioma | | | | |
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies |
|
|
| Completed | 1/2 | 64 | US, RoW | VRx-3996, Nanatinostat, Valganciclovir | Viracta Therapeutics, Inc. | Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders | 04/23 | 05/23 | | |
NCT04724447: ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION |
|
|
| Recruiting | 1/2 | 24 | US | Valganciclovir, Placebo | Laureate Institute for Brain Research, Inc. | Major Depressive Disorder | 12/24 | 12/24 | | |
VT3996-301, NCT05166577: Nanatinostat Plus Valganciclovir in Patients with Advanced EBV+ Solid Tumors, and in Combination with Pembrolizumab in EBV+ RM-NPC |
|
|
| Active, not recruiting | 1/2 | 130 | Canada, US, RoW | Nanatinostat, VRx-3996, Valganciclovir, Valcyte, Pembrolizumab, Keytruda | Viracta Therapeutics, Inc. | Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma, EBV Related Carcinoma, EBV-Related Sarcoma | 12/24 | 10/25 | | |
NCT05595473: A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma |
|
|
| Active, not recruiting | 1/2 | 42 | RoW | RZ-001 Dose 1, RZ-001 Dose 2, RZ-001 Dose 3, RZ-001 Dose 4 | Rznomics, Inc. | Hepatocellular Carcinoma | 03/29 | 05/29 | | |
NCT06102525: A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Glioblastoma |
|
|
| Recruiting | 1/2 | 43 | RoW | RZ-001, Ad-ECRT-122T, VGCV, Valganciclovir | Rznomics, Inc. | Glioblastoma | 03/29 | 05/29 | | |
NCT06302140: A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers |
|
|
| Recruiting | 1 | 14 | Europe | [14C]-Nanatinostat, Nanatinostat (free base) tablets in combination with Valganciclovir, Nanatinostat mesylate tablets in combination with Valganciclovir, Single-agent Nanatinostat (free base) tablets | Viracta Therapeutics, Inc. | Advanced Cancer | 02/25 | 10/25 | | |
NCT06391918: Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 91 | US | GEN2 + Valganciclovir | GenVivo, Inc. | Solid Tumor, Adult | 03/27 | 03/28 | | |
| Temporarily Not Available | N/A | | US | RZ-001 | Rznomics, Inc. | Glioblastoma | | | | |
NCT01049633: B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure |
|
|
| No Longer Available | N/A | | US | Allogeneic Pancreatic Islet Cells, Sirolimus, Basiliximab, Tacrolimus, Antibacterial, Antifungal, and Antiviral Prophylaxis, Trimethoprim/sulfamethoxazole, Septra SS, Clotrimazole, Mycelex Troche, Valganciclovir, Valcyte, Heparin, Anticoagulation and Hematological Agent, Enoxaparin, Lovenox; Anticoagulation and Hematological Agent, Pentoxifylline, Aspirin, ASA | National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | | | | |
| Recruiting | N/A | 40 | Canada | | University of Alberta | Cytomegalovirus Infections | 12/24 | 12/24 | | |
NCT03511118: Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants |
|
|
| Recruiting | N/A | 1600 | Canada, US | Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine | Duke University, The Emmes Company, LLC, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI | 09/24 | 07/26 | | |
NCT05238220: Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients |
|
|
| Completed | N/A | 37 | US | Valganciclovir | Piedmont Healthcare, ViraCor Laboratories | Kidney Transplant; Complications | 06/22 | 06/22 | | |
